Modulation of Tumor Microenvironment by a Designer Scaffold with Immune Checkpoint Blockade Enhance Cancer Immunotherapy
발표자
()
초록
내용
Regression of malignant tumors after post-surgical removement remains a clinical obstacle. Immune checkpoint blockade (ICB) implementation to overcome this obstacle by eliciting durable antitumor responses still holds limitation of low efficiency, which is due to fortified pro-tumoral environment after surgery. Here a promising platform, designer scaffold loaded with immune nanoconverters encapsulated with resiquimod (iNCVs (R848)) and doxorubicin, is introduced to polarize the immunosuppressing cells such as tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs) to antigen-presenting cells (APCs), and simultaneously ameliorating antitumor response with low systemic toxicity, forming immunogenic TME. Along with TME modulation, duration of memory T cells specific to neoantigen prevents tumor recurrence and metastasis. Introduction of the spatiotemporal modulating designer scaffolds suggests immunogenic therapy that overcomes current limitations.